Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/27/2025

Pneumococcal Vaccine Safety Profile

Common Side Effects

  • The Centers for Disease Control and Prevention recommends that pneumococcal vaccines generally have mild side effects, with approximately half of recipients experiencing local reactions such as pain, redness, and swelling at the injection site that typically resolve within 48 hours 1
  • Pain at the injection site, erythema (redness), and swelling are the most common side effects, occurring in approximately one-third to half of vaccine recipients, according to the Centers for Disease Control and Prevention 1, 2
  • Injection site erythema (28-30%), injection site pain (24%), and injection site swelling (18%) are the most frequently reported adverse events, as reported by the Centers for Disease Control and Prevention 2
  • Fever (22%) is among the most common systemic side effects, particularly in adults aged 19-64 years, according to the Centers for Disease Control and Prevention 2

Safety Profile by Vaccine Type

  • A postlicensure review of PCV13 using VAERS data showed that 94.1% of reported adverse events were nonserious, as reported by the Centers for Disease Control and Prevention 2
  • The most common adverse events in persons aged ≥65 years receiving PCV13 were injection site erythema (30%), general erythema (20%), and injection site swelling (18%), according to the Centers for Disease Control and Prevention 2
  • No increased rate of adverse events was observed after PCV13 administration in persons aged ≥65 years compared with PPSV23 in a large cohort study, as reported by the Centers for Disease Control and Prevention 2
  • PPSV23 is generally considered safe based on clinical experience since 1977, according to the Centers for Disease Control and Prevention 1

Serious Adverse Events

  • Severe systemic adverse effects such as anaphylactic reactions are rare, as reported by the Centers for Disease Control and Prevention 1
  • No reports of severe febrile or anaphylactic reactions were found in a meta-analysis of nine randomized controlled trials, according to the Centers for Disease Control and Prevention 1
  • No neurologic disorders (e.g., Guillain-Barré syndrome) have been associated with pneumococcal vaccination, as reported by the Centers for Disease Control and Prevention 1
  • Pneumococcal vaccination has not been causally associated with death among vaccine recipients, according to the Centers for Disease Control and Prevention 1

Special Considerations

  • The safety of pneumococcal polysaccharide vaccine during the first trimester of pregnancy has not been fully evaluated, as reported by the Centers for Disease Control and Prevention 1
  • No adverse consequences have been reported among newborns whose mothers were inadvertently vaccinated during pregnancy, according to the Centers for Disease Control and Prevention 1

Contraindications

  • Vaccination with PCV or PPSV23 is contraindicated in persons known to have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, as reported by the Centers for Disease Control and Prevention 4
  • PCVs are also contraindicated in persons known to have had a severe allergic reaction to any diphtheria toxoid–containing vaccine, according to the Centers for Disease Control and Prevention 4

Reporting Adverse Events

  • Healthcare providers should report suspected adverse events after administration of pneumococcal vaccines to the Vaccine Adverse Event Reporting System (VAERS), as recommended by the Centers for Disease Control and Prevention 3